NHS Calderdale Clinical Commissioning Group Logo

Gainshare Agreements (1617088)

1. For your CCG, are there any gainshare agreements in place between you the CCG and a provider (e.g. hospital trust)? A gain share agreement is one where the benefits associated with more efficient us of medicines not reimbursed through national prices is shared between the provider and the clinical commissioning group party to the agreement.

NHS Calderdale CCG has a gain share agreement with Calderdale and Huddersfield Foundation Trust for infliximab and is working on an agreement for etanercept.


2. If “Yes”, then please provide the following details:

a. Disease area

The disease areas are those for which these medicines are used, predominantly rheumatology, gastroenterology and dermatology

b. Provider included in the gainshare agreement

 Please see response to question 1 above.

c. Names of any specific drugs involved

 Please see response to question 1 above.


d. How will savings be apportioned between you the CCG and the provider?

 The savings for infliximab will be apportioned 50-50 between commissioners and providers for 12 months.  After 12 months, savings will be invested in funding new high cost drugs.


3. Who (what position or job role/department) within the CCG is responsible for agreement?

At NHS Calderdale CCG, this agreement is a joint responsibility between Contracting and Medicines Management teams.

NHS Choices
NHS Constitution
NHS Constitution
Disability Confident Employer Badge

NHS Calderdale Clinical Commissioning Group: 5th floor, F Mill, Dean Clough, Halifax, HX3 5AX. Tel: 01422 307400

| Accessibility | Privacy Notice | Glossary of Terms | Work for us |

Icons provided by Icons8. Free Stock Videos by Videezy

© NHS Calderdale CCG 2019